A single intravenous injection of AAV2/9-Endo-Glo1 to express the Glo1 five weeks after HIV infection, attenuated impairments in myocardial diastolic and systolic dysfunctions that developed 16 weeks post-infection (Figures 2, 3, 5). Here, GLO1 is linked to HIV infectious disease.